


Revvity announces launch of new fully automated instrument for specialty testing

20 May 2025 | News

IDS i20 platform features new state-of-the-art software offering a high degree of adaptability and scalability



Revvity, Inc. has announced the launch of its new IDS i20™ analytical random access platform from EUROIMMUN, enabling full automation of chemiluminescence immunoassays (ChLIA).

The IDS i20 platform is a CE marked and FDA listed device that allows laboratories to consolidate multiple specialty tests on a unique single instrument with greater reagent capacity and higher test throughput compared to existing offerings.

The IDS i20 instrument allows users to simultaneously run 20 analytes from six diagnostic specialties on a single device. These specialties include endocrinology, allergy, autoimmune and infectious disease testing, testing for Alzheimer's disease and therapeutic drug monitoring. While specialty assays in these diagnostic areas tend to be processed manually or with semi-automated, low-throughput analyzers, the IDS i20 platform offers labs a new means of more flexible, fully automated ChLIA processing.

With the ability to process up to 140 tests per hour (assay dependent), the IDS i20 instrument is the latest addition to the well-established IDS i-device series, built on more than 50 years of experience in medical device design and innovation.

The IDS i20 platform features new state-of-the-art software offering a high degree of adaptability and scalability, along with a superior graphical user interface that meets the latest standards of ergonomics, usability and cybersecurity. Continuous loading of samples and reagents as well as the integrated cooling of ready-to-use reagent cartridges allow for non-stop operation of the system – maximising efficiency and minimizing hands-on time.